Akari Therapeutics plc ADS AKTX
i
Market datapartial · fetched 2026-11-11T15:39:20.961Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T15:26:39.83046493Z
FundamentalsAlpha Vantage · unavailable
Akari Therapeutics plc ADS options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | ||||||
| 45Δ | ||||||
| 50Δ | ||||||
| 55Δ | ||||||
| 60Δ | 7.34 | 338.3% | 22.0% | |||
| 65Δ | 6.81 | 346.7% | 18.8% | |||
| 70Δ | 6.29 | 355.1% | 15.6% | 10.47 | 293.0% | 6.9% |
| 75Δ | 5.77 | 363.6% | 12.5% | 11.81 | 319.1% | 5.8% |
| 80Δ | 5.25 | 372.0% | 9.3% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
60Δ
- Pseudo strike
- 7.34
- IV
- 338.3%
- B/E move
- 22.0%
- Pseudo strike
- IV
- B/E move
65Δ
- Pseudo strike
- 6.81
- IV
- 346.7%
- B/E move
- 18.8%
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 6.29
- IV
- 355.1%
- B/E move
- 15.6%
- Pseudo strike
- 10.47
- IV
- 293.0%
- B/E move
- 6.9%
75Δ
- Pseudo strike
- 5.77
- IV
- 363.6%
- B/E move
- 12.5%
- Pseudo strike
- 11.81
- IV
- 319.1%
- B/E move
- 5.8%
80Δ
- Pseudo strike
- 5.25
- IV
- 372.0%
- B/E move
- 9.3%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 332.42% | |
| 254.62% | |
| 264.04% | |
| 287.95% | |
| 277.98% | |
| 210.20% |
Biotechnology
ALDX
Aldeyra Therapeutics, Inc., a biotechnology company, develops and markets drugs for immune-mediated systemic and eye diseases. The company is headquartered in Lexington,…
More →ALEC
Alector, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of neurodegenerative diseases. The company is headquartered in South San Francisco,…
More →ALLO
Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The…
More →ALMS
Alumis Inc. (ALMS) is a prominent player in the aluminum sector, specializing in the development and commercialization of high-performance aluminum solutions for automotive,…
More →ALNY
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered…
More →ALT
Description unavailable
More →